在MELD时代,治疗意图生存率没有改善,肝脏非利用率增加
Rei Matsumoto1, Elizabeth C Verna1, Russell Rosenblatt2
1Center for Liver Disease and Transplantation, Columbia University Irving Medical Center, New York, NY.
Transplantation
|April 16, 2024
概括
肝移植存活率有所改善,但意图治疗 (ITT) 存活率并没有显著增加,原因是等候名单中断率和器官不利用率上升. 需要进一步的研究来提高整体肝移植结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 移植医学 移植医学
- 公共卫生 公共卫生
背景情况:
- 近几十年来,肝移植的生存率有所提高.
- 然而,意图治疗 (ITT) 存活率,包括等待名单的持续时间,尚未被彻底研究.
- 了解ITT生存趋势对于评估肝移植的整体有效性至关重要.
研究的目的:
- 分析肝移植候选人的意图治疗 (ITT) 存活率的趋势.
- 调查随着时间的推移,等候名单中断率和器官不使用率的变化.
- 确定影响肝移植中ITT存活率的因素.
主要方法:
- 对移植受体科学注册 (SRTR) 数据库的回顾性分析.
- 包括成年肝移植候选人 (2002-2019) 在内.
- 在同一时期对已故肝脏捐赠者的数据进行分析.
主要成果:
- 移植后的生存率显示持续增加.
- 治疗意图 (ITT) 存活率没有显示出统计学上显著的改善.
- 在研究期间,等待名单中断和肝脏不利用率显著增加.
- 捐赠者风险指数 (DRI) 增加,主要是由于循环死亡 (DCD) 病例后的捐赠.
结论:
- 尽管移植后生存率有所改善,但停滞不前的ITT生存率表明存在系统性问题.
- 增加肝脏非利用可能源于不愿使用高风险器官,影响ITT存活率.
- 对非利用率的进一步调查对于改善肝移植对患者护理的贡献至关重要.
相关概念视频
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


